Mo H - Search Results

1

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Lawitz E, et al. Among authors: mo h. Lancet. 2014 Feb 8;383(9916):515-23. doi: 10.1016/S0140-6736(13)62121-2. Epub 2013 Nov 5. Lancet. 2014. PMID: 24209977 Clinical Trial.

2

Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.

Bae A, Sun SC, Qi X, Chen X, Ku K, Worth A, Wong KA, Harris J, Miller MD, Mo H. Bae A, et al. Among authors: mo h. Antimicrob Agents Chemother. 2010 Dec;54(12):5288-97. doi: 10.1128/AAC.00777-10. Epub 2010 Sep 20. Antimicrob Agents Chemother. 2010. PMID: 20855726 Free PMC article.

3

Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates.

Sun SC, Bae A, Qi X, Harris J, Wong KA, Miller MD, Mo H. Sun SC, et al. Among authors: mo h. J Viral Hepat. 2011 Dec;18(12):861-70. doi: 10.1111/j.1365-2893.2010.01396.x. Epub 2010 Nov 25. J Viral Hepat. 2011. PMID: 21108698

4

Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples.

Bae AS, Ku KS, Miller MD, Mo H, Svarovskaia ES. Bae AS, et al. Among authors: mo h. J Clin Microbiol. 2011 Sep;49(9):3168-74. doi: 10.1128/JCM.00274-11. Epub 2011 Jun 29. J Clin Microbiol. 2011. PMID: 21715590 Free PMC article.

5

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR. Zeuzem S, et al. Among authors: mo h. Hepatology. 2012 Mar;55(3):749-58. doi: 10.1002/hep.24744. Hepatology. 2012. PMID: 22006408 Clinical Trial.

6

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. Lawitz EJ, et al. Among authors: mo h. J Hepatol. 2012 Jul;57(1):24-31. doi: 10.1016/j.jhep.2011.12.029. Epub 2012 Feb 5. J Hepatol. 2012. PMID: 22314425 Clinical Trial.

7

Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy.

Svarovskaia ES, Martin R, McHutchison JG, Miller MD, Mo H. Svarovskaia ES, et al. Among authors: mo h. J Clin Microbiol. 2012 Oct;50(10):3267-74. doi: 10.1128/JCM.00838-12. Epub 2012 Jul 25. J Clin Microbiol. 2012. PMID: 22837328 Free PMC article.

8

Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients.

Dvory-Sobol H, Wong KA, Ku KS, Bae A, Lawitz EJ, Pang PS, Harris J, Miller MD, Mo H. Dvory-Sobol H, et al. Among authors: mo h. Antimicrob Agents Chemother. 2012 Oct;56(10):5289-95. doi: 10.1128/AAC.00780-12. Epub 2012 Aug 6. Antimicrob Agents Chemother. 2012. PMID: 22869562 Free PMC article. Clinical Trial.

9

Development of robust hepatitis C virus genotype 4 subgenomic replicons.

Peng B, Yu M, Xu S, Lee YJ, Tian Y, Yang H, Chan K, Mo H, McHutchison J, Delaney W 4th, Cheng G. Peng B, et al. Among authors: mo h. Gastroenterology. 2013 Jan;144(1):59-61.e6. doi: 10.1053/j.gastro.2012.09.033. Epub 2012 Sep 20. Gastroenterology. 2013. PMID: 23000598

10

A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.

Lawitz EJ, Hill JM, Marbury T, Demicco MP, Delaney W, Yang J, Moorehead L, Mathias A, Mo H, McHutchison JG, Rodriguez-Torres M, Gordon SC. Lawitz EJ, et al. Among authors: mo h. Antivir Ther. 2013;18(3):311-9. doi: 10.3851/IMP2415. Epub 2012 Oct 9. Antivir Ther. 2013. PMID: 23047118 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,316 results

Search Page